Andere talen Perseus Proteomics Inc.

Aandelen

4882

JP3836800007

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
439 ^JPY	-1,79%		+15,83%	-28,96%

10/05	Perseus Proteomics Inc. kondigt uitstel aan voor het einde van de Fase I klinische studie voor Polycythemia Vera	CI
14/02	Perseus Proteomics Inc. rapporteert resultaten voor de negen maanden eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Perseus Proteomics' Interim Report for Phase I Clinical Trial of PPMX-T003 Accepted at 14th JSH International Symposium	18/06
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	10/05
Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)	07/03
Perseus Proteomics Inc. announced that it expects to receive ¥1.566 million in funding	20/02
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	14/02
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	02/02
Perseus Proteomics Secures Japanese Patent for Blood Cancer Drug Candidate	27/12
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13/11
Perseus Proteomics Successfully Enrolls Patients in Phase I Clinical Trial of Anti-TfR1 Antibody for Polycythemia Vera	23-10-23
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)	20-10-23
Perseus Proteomics Launches Sales of Three Antibodies	12-10-23
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents	11-10-23
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology	27-09-23
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia	22-09-23
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture	29-08-23
Perseus Proteomics Inc. Reports Impairment Loss for the First Quarter of the Fiscal Year 2023	14-08-23
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	14-08-23
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14-08-23
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003	29-05-23
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	12-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Perseus Proteomics Inc.

Aandelen

4882

JP3836800007

Andere talen

Filters